Tirzepatide stimulated cAMP production in pancreatic ß-cells, similar to a combination of GLP-1 and GIP [51], while also eliciting better efficacy in controlling cardiovascular disease risk factors such as glucose levels and body weight loss in diabetic patients [148,149]. Here, GLP1R is linked to cardiovascular disorder.